Strategies were also tested in vivo to examine the feasibility of using BE-CAR33 or BE-CLL1 T cells in combination with BE-CAR7 T cells, noting that the latter is already being applied in human studies against T-ALL, and can offer lymphodepleting effects as well as anti-leukaemia activity against CD7+ AML. This evidence concerns the gene CLEC12A and acute myeloid leukemia.